Miriam Del Prado

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties

Mary M. Mader, Alfonso de Dios, Chuan Shih et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 117 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8

Additions of Enantiopure α-Sulfinyl Carbanions to (<i>S</i>)-<i>N</i>-Sulfinimines:  Asymmetric Synthesis of β-Amino Sulfoxides and β-Αmino Alcohols

J.L.G. Ruano, Ana Alcudia, Miriam Del Prado et al. · The Journal of Organic Chemistry · 2000 · 53 citations

Natural Sciences, Chemistry, Organic Chemistry +12

Design of Potent and Selective 2-Aminobenzimidazole-Based p38α MAP Kinase Inhibitors with Excellent in Vivo Efficacy

Alfonso de Dios, Chuan Shih, Beatriz López de Uralde et al. · Journal of Medicinal Chemistry · 2005 · 52 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Ethyl (3<i>S</i>,4a<i>R</i>,6<i>S</i>,8a<i>R</i>)-6-(4-Ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso- quinoline-3-carboxylic Ester:  A Prodrug of a GluR5 Kainate Receptor Antagonist Active in Two Animal Models of Acute Migraine

Sandra Filla, Mark A. Winter, Kirk W. Johnson et al. · Journal of Medicinal Chemistry · 2002 · 51 citations · Full text

Medicine, Neuroscience, Pharmacology +17